Equine Rhodococcus equi Pneumonia in Foals – NAVLE Study Guide

Overview and Clinical Importance

Rhodococcus equi is a gram-positive, facultative intracellular bacterium that causes chronic suppurative bronchopneumonia with abscessation in foals aged 1-5 months. It is the most common and serious cause of pneumonia in young foals and represents a significant economic burden on endemic breeding farms due to prolonged treatment, surveillance costs, and mortality rates of 20-40%.

The disease is insidious in onset, meaning clinical signs often do not appear until pulmonary infection has reached a critical mass. This characteristic makes early detection challenging but crucial for successful treatment outcomes. R. equi is a soil saprophyte found worldwide, with airborne transmission via dust inhalation being the primary route of infection in foals.

Etiology and Epidemiology

Organism Characteristics

Rhodococcus equi (formerly Corynebacterium equi) belongs to the Nocardiaceae family, which also includes Mycobacterium and Nocardia species. Key microbiologic features include:

Epidemiology and Risk Factors

Age susceptibility: Foals are most susceptible between 1-5 months of age, with peak clinical disease occurring at 1-3 months. This correlates with the decline in maternal antibody protection around 6 weeks of age. Foals greater than 6 months rarely develop clinical disease due to maturation of cell-mediated immunity.

Transmission: Foals acquire infection primarily through inhalation of contaminated soil and dust particles containing virulent R. equi within the first few days to weeks of life. Ingestion of contaminated material is a secondary route. The organism multiplies in the intestinal tract of foals, leading to fecal shedding that further contaminates the environment.

Endemic farms: On farms where R. equi is endemic, 5-40% of foals may develop clinical disease, with case fatality rates up to 30%. Hot, dry, and dusty conditions increase environmental bacterial concentrations and disease risk. A direct relationship exists between the number of R. equi organisms in the environment and the incidence of disease.

Pathogenesis and Virulence

Virulence-Associated Plasmid and VapA

The pathogenicity of R. equi is dependent on a large 80-90 kb virulence plasmid (pVAPA) that encodes the virulence-associated protein A (VapA), a surface-expressed lipoprotein essential for intracellular survival and replication within macrophages. Strains lacking this plasmid are avirulent and fail to cause disease in foals.

Key points about VapA:

• VapA expression is thermoregulated, occurring between 34-41°C (body temperature)
• VapA promotes intracellular survival by preventing phagosome-lysosome fusion
• PCR detection of the vapA gene is used for identification of virulent strains
• Environmental isolates typically lack the virulence plasmid and are non-pathogenic

Board Tip - Memory Aid: "VapA = Virulent and Alveolar Pathogen" - Remember that VapA-positive strains are the only ones capable of causing disease in foals. The plasmid enables the bacteria to survive inside alveolar macrophages, which is the key to pathogenicity.

Intracellular Survival Mechanism

After inhalation, R. equi is phagocytosed by alveolar macrophages. Unlike most bacteria that are killed within phagolysosomes, virulent R. equi survives and replicates within a modified phagosome called the "R. equi-containing vacuole" (RCV). The VapA protein prevents:

• Phagosome-lysosome fusion
• Phagosomal acidification (vacuoles remain at near-neutral pH)
• Acquisition of the proton-pumping v-ATPase

This intracellular persistence leads to macrophage destruction by necrosis and formation of characteristic pyogranulomatous lesions with pulmonary abscessation.

Host Immune Response

Cell-mediated immunity (CMI) plays the critical role in clearance of R. equi infection. Key immunological findings include:

• Young foals are deficient in cytotoxic T lymphocytes compared to adults
• Low interferon-gamma (IFN-?) production is a risk factor for infection
• Adult horses completely clear experimental challenge due to robust CMI
• Humoral immunity alone does not provide complete protection

Clinical Signs

Pulmonary Disease

The disease is characteristically insidious and chronic, with clinical signs often not apparent until pulmonary pathology is advanced. The incubation period from infection to clinical signs is typically several weeks to months.

Clinical Signs by Disease Stage

Physical Examination Findings

• Auscultation: Inspiratory and expiratory wheezes and crackles, predominantly cranioventral; decreased lung sounds suggest consolidation or abscessation
• Tracheal palpation: May reveal a rattling sound (hence the colloquial term "rattles")
• Lymph nodes: Mediastinal lymphadenopathy may cause tracheal compression and respiratory noise

Extrapulmonary Disease

Extrapulmonary manifestations occur in approximately 50-74% of foals with pneumonia and may occur independently of pulmonary disease. The prognosis for foals with extrapulmonary involvement is generally less favorable.

Diagnosis

Laboratory Findings

Definitive Diagnosis: Transtracheal/Bronchoalveolar Wash

Gold standard: Isolation of R. equi by culture and/or PCR detection of the vapA gene from tracheobronchial aspirate (TBA) sample in a foal with compatible clinical signs and imaging findings.

• Cytology: Reveals intracellular gram-positive coccobacilli within macrophages and neutrophils; septic inflammation
• Culture: Sensitivity approximately 82% compared to clinical diagnosis
• PCR (vapA gene): Sensitivity and specificity of 100% compared to reference standard; allows identification of virulent strains

Diagnostic Imaging

Thoracic Radiography

Characteristic findings:

• Perihilar alveolar pattern indicating consolidation
• Discrete nodular opacities (abscesses) with or without cavitation
• Mediastinal lymphadenopathy
• Interstitial pattern in early disease

Prognostic indicators: Severity of alveolar pattern and number of cavitary lesions are significantly associated with poor outcome.

Thoracic Ultrasonography

Ultrasonography is the most practical field diagnostic tool for screening and monitoring foals on endemic farms.

Screening criteria: Abscesses ≥15 mm diameter or other pleural lesions are significantly associated with development of clinical disease and warrant treatment consideration. However, many foals with subclinical lesions (less than 15 mm) resolve spontaneously without treatment.

Treatment

Antimicrobial Therapy

The recommended treatment is combination therapy with a macrolide plus rifampin. These antimicrobials are bacteriostatic individually but act synergistically. Their high lipophilicity allows penetration into abscess material and intracellular concentration within granulocytes and macrophages.

Antimicrobial Dosing Protocols

Treatment Duration and Monitoring

• Duration: 4-9 weeks typically; continue until clinical signs resolve AND radiographic/ultrasonographic lesions improve
• Monitoring: Serial hematology (WBC, fibrinogen, globulins), thoracic ultrasound, and radiographs
• Extended treatment: Foals with extrapulmonary disease (septic arthritis, osteomyelitis) may require 3-4 months of therapy

Adverse Effects of Macrolide Therapy

Antimicrobial Resistance Concerns

Resistance to macrolides and rifampin is increasing, with up to 40% of isolates resistant at some endemic farms. Resistance is linked to mass antimicrobial treatment of subclinically affected foals identified through ultrasonographic screening.

Alternative antimicrobials (based on susceptibility testing): gentamicin, fluoroquinolones, chloramphenicol, vancomycin, imipenem, doxycycline, trimethoprim-sulfamethoxazole. However, many have significant limitations (nephrotoxicity, arthropathy in young animals).

Supportive Care

• Clean, well-ventilated environment with minimal dust exposure
• Nutritional support and adequate hydration
• NSAIDs (flunixin, meloxicam) for fever control (maintain temperature less than 103.5°F)
• Intranasal oxygen for severe respiratory compromise
• Gastroprotectants for stressed foals

Prognosis

Overall survival rate: 60-90% with appropriate treatment, depending on disease severity and early intervention.

Prevention and Control

Management Strategies

• Environmental management: Minimize dust exposure; avoid overcrowded, dry paddocks; provide well-ventilated housing; remove manure frequently
• Foal management: Foal in clean stalls without dirt floors; move foals to grass pasture rather than dusty paddocks after several weeks
• Isolation: Remove ill foals from group settings; manage manure appropriately as pneumonic foals shed high numbers of bacteria

Hyperimmune Plasma (HIP)

Administration of R. equi-specific hyperimmune plasma may decrease the incidence and severity of disease but is not completely protective. Efficacy remains debated in the literature.

• Typical protocol: 1 L IV within first few days of life, repeated at approximately 25 days of age
• Recent evidence: 2 L within 48 hours of birth may provide superior protection compared to 1 L

Screening Programs

On endemic farms, screening programs help detect subclinical disease:

• Serial thoracic ultrasonography: Every 2-4 weeks; most widely adopted approach
• Fibrinogen monitoring: Every 2 weeks; useful early indicator
• Daily temperature and respiratory rate: Performed by farm staff

Vaccination

No licensed vaccine is currently available for prevention of R. equi in foals. Conventional vaccine strategies (live-attenuated, killed) have been ineffective due to the importance of cell-mediated immunity. Research into novel vaccine approaches (DNA plasmid vaccines, vector-based vaccines) is ongoing.